News | Heart Failure | February 24, 2023

Abiomed at CRT 2023: Benefits of Impella-Supported High Risk PCI and Impella Innovation

Featured presentation on the time to clinical benefit of sotagliflozin in people with worsening heart failure

Featured presentation on the time to clinical benefit of sotagliflozin in people with worsening heart failure

February 24, 2023 —  Abiomed, Inc., part of Johnson & Johnson MedTech[1], announced that results from a study on Impella-supported high-risk percutaneous coronary intervention (HRPCI) patients will be presented during the upcoming Cardiovascular Research Technologies (CRT) 2023 Conference in Washington, DC from Feb. 25-28. Abiomed’s booth (#503) and Saturday’s Power Break lunch symposium will feature the latest Impella technologies. Several Live Cases with physicians using Impella technology will be broadcast throughout the conference to attendees. 

Oral Presentation 

Named one of the top oral presentations at CRT 2023, Arsalan Abu-Much, MD, from the Cardiovascular Research Foundation, will highlight results from a PROTECT III analysis of 1,237 non-cardiogenic shock patients who received an Impella supported HRPCI. 

  • Title: Impella Utilization In High-risk Percutaneous Coronary Intervention Mitigates The Risks Of Procedural And Clinical Adverse Events Independent Of Left Ventricular Ejection Fraction: The Protect III Study 
  • Date/Time: Sunday, Feb. 26, 2:30-2:40 pm ET, Kent Theater 

Symposium – High Risk, High Reward – Modern Impella Utilization 

On Saturday, Feb. 25 at 1 pm ET, Abiomed is sponsoring a lunch symposium focused on Impella utilization during HRPCI. Four physicians, listed below, will discuss how to identify appropriate patients for HRPCI with Impella support as well as optimizing outcomes for these patients. Two Impella HRPCI cases will also be featured, including one case utilizing Impella ECP, the world’s smallest heart pump at 9 Fr. 

Abiomed Technology Highlights 

At the Abiomed booth (#503), visitors will have the opportunity to learn more about a recent labeling change for Impella CP with SmartAssist and get hands-on demonstrations with Abiomed’s latest technologies. The U.S. Food and Drug Administration (FDA) recently validated the best practice of placing Impella pre-PCI in cardiogenic shock patients. The FDA’s decision is based on multiple studies and publications and a recently published AHA Scientific Statement, which says physicians should consider Impella prior to initiation of PCI in patients presenting with signs and symptoms of cardiogenic shock. The following technologies will be featured at the booth: 

  • Impella RP Flex with SmartAssist is implanted percutaneously through the internal jugular vein, which provides the option for patient mobility while on support and is designed to be easy to implant, with a flexible canula that is advanced over an extra supportive guidewire. 
  • Impella Low Profile Sheath has smaller size and technological advancements that facilitates easier Impella insertion and removal, reduces procedural steps and helps improve outcomes. 
  • 9th generation of Impella CP with SmartAssist has a new tapered, more flexible pigtail that enables easier insertion and is compatible with heparin-free purge, sodium bicarbonate, to help with anticoagulation management. 

For more information: www.abiomed.com 

Related Impella Content: 

VIDEO: Demonstration of Abiomed Impella ECP 9 French Transcatheter Ventricular Assist Device 

VIDEO: Abiomed Highlights Trends and New Technology in Hemodynamic Support 

FDA Approves First-in-Human Trial of Impella ECP World’s Smallest Heart Pump 

VIDEO: Demonstration of the Impella Percutaneous Hemodynamic Support Device 

VIDEO: Tufts Uses a Hemodynamic Support Algorithm to Determine What Devices to Use — Interview with Navin Kapur, M.D. 

Photo Gallery of the Abiomed Impella Production Line 

VIDEO: Door-to-Unloading (DTU) Trial May Change STEMI Care — Interview with Navin Kapur, M.D. 

VIDEO: Hemodynamic Support Protocols at Henry Ford Hospital — Interview with William O'Neill, M.D. 


Related Content

News | Heart Failure

March 28, 2023 — People exposed to low doses of ionizing radiation have an extra, but modest, risk of developing heart ...

Home March 28, 2023
Home
News | Heart Failure

March 24, 2023 — Abbott announced new data that found monitoring patients remotely with hemodynamic pressure sensing ...

Home March 24, 2023
Home
News | Heart Failure

March 21, 2023 — Procyrion, Inc., a medical device company dedicated to improving outcomes for patients with cardiac and ...

Home March 21, 2023
Home
News | Heart Failure

March 21, 2023 — CVRx, Inc., a commercial-stage medical device company focused on developing, manufacturing and ...

Home March 21, 2023
Home
News | Heart Failure

March 5, 2023 — Doctors who received customized electronic health record (EHR) alerts for specific patients were 2.5 ...

Home March 05, 2023
Home
News | Heart Failure

March 4, 2023 - Lexicon Pharmaceuticals, Inc. announced new analyses of results from the SOLOIST-WHF Phase 3 outcomes ...

Home March 04, 2023
Home
News | Heart Failure

March 3, 2023 — Researchers may be able to predict cardiovascular disease – such as atrial fibrillation and heart ...

Home March 03, 2023
Home
News | Heart Failure

February 23, 2023 — Lexicon Pharmaceuticals, Inc. announced the upcoming presentation of new analyses of results from ...

Home February 23, 2023
Home
News | Heart Failure

February 22, 2023 — CVRx, Inc., a commercial-stage medical device company focused on developing, manufacturing and ...

Home February 22, 2023
Home
News | Heart Failure

February 2, 2023 — Technology is continuously evolving, and so is the approach taken by transplant cardiologists at ...

Home February 02, 2023
Home
Subscribe Now